PMID- 36115316
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20221028
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 202
DP  - 2022 Oct
TI  - Effectiveness of pulmonary rehabilitation in individuals with Chronic Obstructive 
      Pulmonary Disease according to inhaled therapy: The Maugeri study.
PG  - 106967
LID - S0954-6111(22)00232-3 [pii]
LID - 10.1016/j.rmed.2022.106967 [doi]
AB  - BACKGROUND AND AIM: Real-life studies report discordant prescribing of inhaled 
      triple therapy (TT) among individuals with COPD. Guidelines recommend pulmonary 
      rehabilitation (PR) for persistent breathlessness and/or exercise limitation. 
      This real-life study aimed to assess the effects of in-patient PR in individuals 
      under TT as compared to other inhaled therapies (no TT). METHODS: Multicentric, 
      retrospective analysis of data from individuals admitted to in-hospital PR. 
      Baseline characteristics were recorded and lung function was assessed. Outcome 
      measures were: 6-min walking test (6MWT: primary outcome), Medical Research 
      Council (MRC) scale for dyspnoea, and COPD assessment test (CAT). RESULTS: Data 
      of pre and post program 6MWT of 1139 individuals were available. Pulmonary 
      rehabilitation resulted in significant improvement in 6MWT in both groups, 
      however, the effect size (by 54.3 +/- 69.7 vs 42.5 +/- 64.2 m, p = 0.004) and 
      proportion of individuals reaching the minimal clinically important difference 
      (MCID) of 6MWT (64.2%, vs 54.3%, p = 0.001) were higher in TT group. Both groups 
      significantly improved also the other outcome measures. The significant 
      independent predictors of reaching the MCID of 6MWT were hospital provenience, TT 
      use, and high eosinophils count. CONCLUSION: Pulmonary rehabilitation results in 
      significant benefits in individuals with COPD irrespective of the use of TT. 
      However, individuals under TT report larger benefits in exercise tolerance than 
      those under no TT.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Vitacca, Michele
AU  - Vitacca M
AD  - Respiratory Rehabilitation of the Institute of Lumezzane, Istituti Clinici 
      Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy. Electronic address: 
      michele.vitacca@icsmaugeri.it.
FAU - Paneroni, Mara
AU  - Paneroni M
AD  - Respiratory Rehabilitation of the Institute of Lumezzane, Istituti Clinici 
      Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy.
FAU - Spanevello, Antonio
AU  - Spanevello A
AD  - Respiratory Rehabilitation of the Institute of Tradate, Istituti Clinici 
      Scientifici Maugeri IRCCS, Tradate, Varese, Italy; Department of Medicine and 
      Surgery University of Insubria, Varese, Italy.
FAU - Ceriana, Piero
AU  - Ceriana P
AD  - Respiratory Rehabilitation of the Institute of Pavia, Istituti Clinici 
      Scientifici Maugeri IRCCS, Pavia, Italy.
FAU - Balbi, Bruno
AU  - Balbi B
AD  - Respiratory Rehabilitation of the Institute of Veruno, Istituti Clinici 
      Scientifici Maugeri IRCCS, Veruno, Novara, Italy.
FAU - Salvi, Beatrice
AU  - Salvi B
AD  - Respiratory Rehabilitation of the Institute of Lumezzane, Istituti Clinici 
      Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy.
FAU - Ambrosino, Nicolino
AU  - Ambrosino N
AD  - Respiratory Rehabilitation of the Institute of Montescano, Istituti Clinici 
      Scientifici Maugeri IRCCS, Montescano, Pavia, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220827
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Bronchodilator Agents)
SB  - IM
MH  - Administration, Inhalation
MH  - Bronchodilator Agents
MH  - Dyspnea
MH  - Exercise Therapy/methods
MH  - Exercise Tolerance
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Airflow limitation
OT  - Bronchodilators
OT  - CAT
OT  - COPD triple therapy
OT  - Dyspnoea
OT  - Exercise capacity
OT  - Exercise training
OT  - Inhaled steroids
COIS- Declaration of competing interest The authors have no conflict of interest to 
      disclose related to this manuscript.
EDAT- 2022/09/18 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/09/17 18:29
PHST- 2022/06/28 00:00 [received]
PHST- 2022/08/18 00:00 [revised]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/09/18 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/17 18:29 [entrez]
AID - S0954-6111(22)00232-3 [pii]
AID - 10.1016/j.rmed.2022.106967 [doi]
PST - ppublish
SO  - Respir Med. 2022 Oct;202:106967. doi: 10.1016/j.rmed.2022.106967. Epub 2022 Aug 
      27.